BioCentury
ARTICLE | Clinical News

Aldeyra planning Phase III program for dry eye disease therapy

September 26, 2018 4:53 PM UTC

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) added $3.45 (35%) to $13.35 on Wednesday after reporting that reproxalap (ADX-102) significantly reduced ocular dryness and discomfort in a Phase IIb trial to treat dry eye disease. The company plans to start Phase III testing of the candidate next year.

Aldeyra shares touched an all-time high of $16.70 on Wednesday, almost four times their value in September 2017 before the company issued data from a Phase IIa trial of reproxalap in the indication (see "Aldeyra Gains on Phase IIa Data for Dry Eye Candidate")...

BCIQ Company Profiles

Aldeyra Therapeutics Inc.